Dynogen Research Operation Aquired by Astellas Pharma Inc.
Dynogen Pharmaceuticals, Inc. and Astellas Pharma, Inc. announced that Astellas has acquired Dynogen's North Carolina-based research facility. Financial details regarding the sale were not disclosed. The research facility specializes in state-of-the-art preclinical studies for genitourinary disorders.
"We've built an impressive clinical and preclinical pipeline through our unique understanding of the neuroscience underlying gastrointestinal and genitourinary disorders, leveraging that knowledge to generate strong intellectual property and utilizing that intellectual property to enable an aggressive inlicensing program," said Lee R. Brettman, M.D., President and CEO of Dynogen. "We've maximized the value of the North Carolina facility in this effort, and now will focus all of our efforts on advancing the development of our five clinical programs and our late-stage preclinical programs."
Other news from the department business & finance
